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Abstract
Tuberculosis (TB), one of the most widespread infectious diseases, is the leading cause of 
death in the world and has been known in humans since ancient time. The epidemi
trends of tuberculosis since the pre-chemotherapy era to the current both in developed 
countries and developing countries are presented in this review. A declining trend of 
magnitude of TB have been observed in most of the developed countries since the beginning 
of 20
th
 century with modification of life standard but after the introduction of chemotherapy,  it 
changed in to upward trend because of  HIV epidemic, socio
emergence of multi-drug resistance TB (MDR
observed in most of the developing countries including Ethiopia even after the introduction of 
chemotherapy, and those   factors that have been led to i
developed countries   further also led to worsening of the problem in developing countries. The 
Global incidence of TB showed a decline between the years of 2000
expected to increase further in the coming years, more significantly in the countries of Africa 
and South-East Asia including Ethiopia because of change in demographic factors (population 
growth), increase in the global incidence of 
mycobacterium and changes in age structure of the population and increase in HIV sero
prevalence rates, especially in developing countries of South
Africa. This calls for more intensive and su
infection and reducing transmission through  increasing health service facility and decreased 
contributing factories, run all the research activities will up




Tuberculosis (TB), one of the most widespread 
infectious diseases, is the leading cause of death in 
the world and has been known in humans since 
ancient time. The skeletal remains have been 
showed that prehistoric humans (4000 BC) had TB, 
and tubercular decay has been found in the spines 
of mummies from 3000-2400 BC (Zink 
Phthisis is a Greek term for TB; around 460 BC, 
Hippocrates identified phthisis as the most 
widespread disease of the time. Genetic studies 
suggest that TB was present in South America
about 2,000 years (Konomi et al., 2002).
 
Although it was established that the pulmonary 
form of TB was associated with 'tubercles' by 
Richard Morton in 1689 (Trail, 1970), due to the 
variety of its symptoms, TB was not identified as a 
single disease until the 1820s and was not named 
Wollega University, Ethiopia. 
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'tuberculosis' until 1839 by  Schönlein
causing TB, Mtb, was identified and described on 
March 24, 1882 by Robert Koch (Ismael Kassim and 
Ray, 2004).  
 
TB, or 'consumption' as it was commonly known, 
has caused the most widespread public concern in 
the 19th and early 20th centuries as an 
disease of the urban poor such as, in England , in 
1815, one four deaths was caused  by consumption 
and in  1918, one in six deaths in France were still 
caused by TB. In the 20th century
killed an estimated of 100 million people (Torrey and 
Yolken, 2005). Recently, over one
world's population has been exposed 
approximately over two billion people worldwide 
carry the bacterium that causes TB, while about 15 
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million people suffering from an active infection at 
any one time (WHO, 2006). 
 
Developing countries bear the burden of the TB 
epidemic. An estimated of  95% of TB cases and 
98% of TB deaths occur in the developing world 
where people are especially vulnerable to TB 
because of poor living conditions and limited access 
to treatment. Just five countries—Bangladesh, 
China, India, Indonesia, and Pakistan—account for 
nearly half the new cases each year (WHO, 2006, 
and Raviglione and O'Brien, 2004). 
 
Estimation shows that in sub-Saharan Africa 
alone,  there are 1.3 million new cases of TB and 
50,000 deaths annually (Porter and Adam, 
1992).The young and most productive segments 
age groups of the population is seriously affected by 
the disease with  the infection rate goes up to 50% 
in this group (Styb1o et al., 1996). In Ethiopia, TB is 
among the leading cause of mortality and morbidity 
(Azbite, 1991). 
 
Although  Mtb  is the most common cause of 
human TB, unknown proportion of cases are due to 
Mycobacterium bovis (Mb) and other mycobacterial 
infection such as, Mycobacterium africanum, 
Mycobacterium canetti, and Mycobacterium microti 
(Acha and Szyfres, 1987).  
               
 
Even though TB could be transmitted by 
ingesting infected meat and milk, mostly the disease 
is spread by aerosols created by coughing or 
sneezing. Transmission can only occur from people 
with active-not latent-TB. People with prolonged, 
frequent, or intense contact with patient are at 
particularly high risk of becoming infected, with an 
estimated infection rate of   22% (Nicas et al., 2005, 
CDC, 2005, and Waddington, 2004). 
 
The disease  most commonly attacks the lungs 
(PTB) but can also affect the central nervous 
system, the lymphatic system, the circulatory 
system, the genitourinary system, bones, joints and 
even the skin (Herrmann and Lagrange, 2005).  
 
This paper presents the past, present and futures 
global epidemiological trends of TB with the aims of 
providing information on its control and prevention 
strategies to mitigate the problems especially in the 
developing world. 
 
Epidemiology of Tuberculosis  
Tb is one of most widespread infectious disease, 
and a leading cause of death in the world .It has 
been known in human since ancient time, and it 
cause many public health problems throughout 
these times until its problem more aggravated by 
currently contributing factor such as , HIV epidemic, 
socio-demographic factors and emergence of multi-
drug resistance TB (MDR-TB). 
 
In this paper the epidemiology of TB is presented 
in to five epidemiological periods. These are namely 
pre –chemotherapy era (before 1949), following 
introduction of chemotherapy (1949-1980), recent 
epidemiology (1980-2000), current epidemiology 
(2000-2006) and future epidemiology of TB (2006-
2020). 
 
Epidemiology of TB in Pre-Chemotherapy Era 
 
Developed countries 
There are ample evidences that TB had been a 
serious problem in developed countries since the 
turn of 20
th
 century. Disease specific mortality data 
show that TB in England peaked around 1740 with 
about 900 TB deaths per lakh population per year. 
Most of the capitals of other western European 
countries attained their mortality peaks in first half of 
l9th century a decade’s later (Grigg, 1958). TB 
mortality declined considerably from 200 - 400/lakh 
population per year at the turn of the century during 
the next 40 years in Czechoslovakia, Norway, 
Netherlands and other developed countries 
including USA. Mortality records in Canada showed 
3% per annum decline in TB mortality prior to 
introduction of specific treatment (Styblo et al., 
1969).  
 
Information on TB morbidity during pre 
chemotherapy era available from few countries also 
indicated a decline in disease rates .In Denmark, 
the incidence of cases fell by 58% from 1921 to 
1940. New cases of bacillary PTB also decreased in 
Norway from 1927 to 1947, more in pediatric age 
group (Raviglione et al., 1993). In Netherlands, 
5.4% annual decline in annual risk of infection (ARI)   
was observed in the pre-chemotherapy era. 
Repeated tuberculin surveys in children showed 
3.8% annual decline in the risk of infection in Vienna 
and 4.7% in Prague (Styblo, 1978). A similar decline 
was also observed in France (Styb1o, 1991). In fact, 
introduction of milk pasteurization in 1940s in most 
of the European countries leading to drastic 
reduction in transmission of bovine TB was also 
responsible for the decline in the prevalence rates of 
TB infection among human populace in these 
countries. Since chemotherapy was not-exists 
during this period and BCG vaccination does not 
affect transmission of infection, this trend in 
developed countries associated with improvement 
of life standered. 
 
Developing Countries 
Only a little information about TB situation and its 
trend during the first half of 20 century is available 
from developing countries because of lack of 
reliable data on mortality and morbidity of TB or 




even prevalence of infection. In Alaska, TB mortality 
accounting for 35% of all deaths remained constant 
at 65 per lakh population from 1920 to 1950 (WHO, 
1998). Tuberculin surveys carried out in Algeria and 
Tunisia showed negligible decline in risk of infection 
from 1938 to 1948 (Styb1o, 1991). Therefore, an 
inference can be drawn that in contrast to 
developed countries, there was no downward trend 
in the TB problem prior to chemotherapy era in the 
developing countries. 
 




After 1945, the fall in TB mortality rates 
accelerated in countries of Western Europe and 
North America (Styb1o, 1991). This coincided with 
introduction of Streptomycin in 1946, Para amino 
salicylic acid (PAS) in 1948 and isoniazid (INH) in 
1952 (Chadha, 1997).The incidence of new cases of 
TB also showed similar declining trends in most of 
the developed countries. In Federal Republic of 
Germany, incidence rate of bacteriologically 
confirmed cases declined from 78 per lakh 
population in 1949 to 15 per lakh in 1979 (Styb1o, 
1991). Similar decline was observed for 
bacteriologically unconfirmed and extra pulmonary 
cases. In Canada, complete coverage of the 
population with case finding and treatment was 
achieved by 1957. Since large proportion of 
population was already infected, notification rates 
were not immediately affected but later on declined 
at the rate of 10% per annum (Raviglione et al., 
1993) and most of the new cases occurred in elderly 
and old persons. In Netherlands, morbidity of TB in 
younger people (0-30 years) fell by about 12% per 
year (Styblo, 1991). 
 
In New Zealand (NZ), TB notification steadily 
declined after the Second World War and reached a 
nadir of 295 in 1988. In subsequent years, between 
300 and 450 cases have been reported annually 
with a notification rate of around 10 per 100,000 
(Turnbull, 2002). 
 
In most of the developed countries like Canada, 
Federal Republic of Germany, France, Britain and 
Norway, 12-13% annual decline in risk of infection 
was observed after introduction of case finding and 
treatment programmes which is higher rates  in 
relative to 4-5% decline per annum prior to 
chemotherapy (WHO, 1998). Similarly, in 
Netherlands, the risk of infection decreased rapidly 
by 15% per annum during 1951-1970 because of 
high sputum conversion rates achieved on 
treatment of bacillary cases (Styblo, 1978). Thus, 
TB problem declined rapidly after the advent of 
chemotherapy in developed countries, especially 
among children and young adults. 
Developing Countries 
Morbidity data from developing countries are 
incomplete since only a third of the new smear 
positive cases are detected annually and thus 
cannot be relied upon for assessment of TB 
problem. Moreover, comparison with developed 
countries is undesirable since definition of a new 
case differs depending upon the resources available 
for diagnosing a case. The main source of 
information for studying the epidemiological 
situation of TB in developing countries is tuberculin 
surveys for estimation of ARI. The risk of TB 
infection remains high in most developing countries 
and on an average, it is estimated to be 50 to 100 
times of that in developed countries. Most data from 
African countries indicate that the ARI after 
introduction of chemotherapy was around 1 to 2.5 
percent. Though a slow decline has been observed 
in countries like Ethiopia, Cameroon, Burundi, 
Boatswana and moderate decline in Algeria, no 
such decline has been observed in other countries 
like Tanzania, Lesotho and rural Gambia. In 
addition, those of East Europe, a few of the Latin 
American countries, lower risks of infection at less 
than 1 percent have been recorded (WHO, 1998). 
However, the steep decline observed in earlier 
years in cities of Argentina appears to have been 
averted of late. On the other hand, ARI in Brazil on 
an average is high at 1-2 percent with wide variation 
between different regions of the country. ARI of 5-
10% was observed in south and south East Asian 
countries in 1950s and continues to be high in most 
countries of this region despite availability of 
chemotherapy (WHO, 1998). This incensement was 
highest in Indonesia where an actual incensement 
of 3 to 4% was reported in some regions. Similarly, 
ARI rates were high in India with the 1 to 2.5 
percentage (Chakraborty, 1993) and in Thailand 
more than 2% with no signs of any declining trends 
(WHO, 1998). 
 
In the eastern Mediterranean region, ARI rates 
were high in Pakistan at around 2% and in 
Afghanistan at around 2.5%. However, low recent 
levels of infection risks have been reported in most 
of the Middle East countries like Baharain, Libya, 
Kuwait and Syria after steep decline after 
introduction of chemotherapy. In the Western Pacific 
region, ARI remains high in Korea and Philippines at 
about 2% and 1% in China, though it was relatively 
low in Malaysia (WHO, 1998). 
 
The above data suggests that though 
improvement in living standards and TB control 
activities led to reduction in ARI in some of the 
developing countries like in developed ones, ARI in 
most other countries remains high with no indication 
of any decline. Thus, the problem of TB remained 
high in most of the developing countries even after 




the advent of chemotherapy. This was mainly 
because of low case-finding efficiency and poor 
treatment programmes. 
 
Recent Epidemiology of Tuberculosis 
Just when it was being projected that TB has 
been conquered in the west, research was stopped 
and funding was decreased; there was a dramatic 
change in epidemiological situation of TB. The 
declining trend of TB in industrialized countries and 
some of the middle-income countries since the 
beginning of the century witnessed a reversal after 
mid-eighties, because of the advent of HIV epidemic 
and other socio-demographic factors. There was 
further worsening of the TB problem in developing 
countries as well (Chadha, 1997). Besides, the 
worldwide incidence of HIV-attributable TB cases is 
estimated to increase from 315,000 (4% of the total 
TB cases) in 1990 to 1.4 million (14% of the total TB 
cases) by the year 2000. After these change in the 
trend of TB, WHO declared it as a global emergency 
in 1993 and stressed the need for concerted efforts 
to curb the spread of the epidemic (WHO, 2003). 
 
Developed Countries 
The recent epidemiological trend of TB in 
developed countries can be most appropriately 
illustrated by the TB situation in USA where, after a 
dramatic decline in the incidence of TB during early 
decay of  20
th
 century, there has been a 20% 
increase in the disease notification rates from 1985 
to 1992 (Chadha, 1997). Most of the increase is 
accounted for those heavily populated urban areas 
that have greatest concentration of Asian Blacks 
and foreign-born immigrants from countries with 
high prevalence of TB. These are also the areas 
with highest incidence of reported AIDS cases. 
Overall 31% of the rise in incidence of TB in USA is 
attributed to HIV epidemic. Significantly, the median 
age of persons with TB decreased from 49 years in 
1985 to 43 years in 1992 mainly due to increase in 
incidence among 25-44 years aged people, who are 
most affected by HIV epidemic. Increased 
transmission of infection has also resulted in higher 
incidence among 0-4 years aged children. The 
increase in cases of MDR- TB, mainly in urban and 
minority population due to rising number of 
intravenous drug users who also have high 
prevalence of HIV infection and  homeless persons 
because of their erratic living situations and non-
adherence to chemotherapy is an added variable 
responsible for the recent rising trend of TB. The 
isolates with drug resistance tended to come from 
younger persons indicating that drug resistance was 
associated with more recent infections. 
 
In Australia, crude notification rate for all active 
TB declined from 12.2 per 1,00,000 population in 
1975 to 5.2/1,00,000 in 1986, after which the 
notification rate increased steadily to 7.6/1,00,000 in 
1995 (Heath, 1998).  
 
In Canada,  incidence has remained constant 
since 1986 while in Japan, there is slowing down of 
the declining trend, and in New Zealand, an actual 
increase in case notifications has been observed 
recently. Majority of the cases in these countries 
were reported among foreign born individuals 
(Turnbull, 2002). While no data is available about 
the impact of HIV epidemic on TB in Canada, 
adverse impact has been observed in Australia, 
New Zealand and Japan. 
 
Similar trends have been observed in west 
European countries such as, England, Italy and 
Switzerland. In England, where notification rates 
were falling ever year, rose for the first time in 1991 
by 4% than the previous year. Immigrants from Asia 
and East Europe were the worst affected. There 
was 20% increase in areas with highest number of 
AIDS patients. In Italy, where TB is common among 
HIV infected persons, and in Switzerland, a increase 
in 30% was observed from 1986 to 1990 years. 
High levels of HIV sero-prevalence have also been 
observed in certain urban areas of France and 
Spain leading to rise in reported TB cases 
(Raviglione et al., 1993).  
 
In Eastern Europe, HIV problem is poorly defined 
and not yet considered as important factor for 
epidemiology of TB. However, increase in TB 
incidence has been observed in many countries 
mainly due to disturbed conditions because of 
economic and civil strife, resulting in shifting of 
priorities, breakdown of drug supply and health care 
system (WHO, 1994).Therefore, the recent trend of 
TB in developed countries was increase in its more 
public health important epidemic form as compared 
to just after chemotherapy era that have been more 
indicated from Table 1. 
 
Developing Countries 
While resurgence took place in developed world 
after years of continuous decline, it was never 
controlled in developing world and more recently, 
there has been further rise in TB cases, especially 
in Africa and South East Asia. At present, Africa 
account for more than 75% of dually infected 
persons with HIV and TB (WHO, 1994). HIV is the 
major cause of large increase in incidence of TB in 
a number of sub-Saharan countries. Some of these 
countries have experienced a 3 or 4 fold increase in 
TB case notification and deaths as a result of HIV 
associated TB. HIV seroprevalence rates of more 
than 40% are common among patients with TB in 
many African countries and even higher rates have 
been observed among extrapulmonary cases 
(Narain et al., 1992, and Dolin et al.,1993). Overall, 




30-40% of TB cases in Africa and Caribbean 
countries are attributable to HIV. In HIV affected 
African countries, TB has been reported in 20-44% 
of AIDS patients. Thus, TB is becoming one of the 
most common opportunistic diseases associated 
with AIDS (Narain et al., 1992). South East Asia and 
western pacific region contribute more than 60% of 
global TB incidence and HIV is making rapid in 
roads in several Asian countries including India, 
Thailand and Myanmar (WHO, 1994). This may 
result in significant increase in TB cases in Asia, as 
almost two-thirds of the world’s TB-infected 
population lives in Asia. HIV seroprevalence among 
TB patients is on the rising in South East Asia. In 
one region of Thailand, it rose from 5.1 % in 1989 to 
14% in 1991 (Narain et al., 1992). 
 
High HIV seroprevalence rates have been 
observed in some of the Latin American countries 
like Haiti, Honduras, Argentina and Brazil (WHO, 
1994). In the Eastern Mediterranean and western 
pacific regions, HIV seroprevalence rates among TB 
cases are not available for most countries. 
 
MDR-TB, which was thought to be an 
insignificant problem outside USA, now                                                                                       
spreading to different part of the world including 
developing countries. There are reports of rising of 
MDR-TB developing countries. This may further 
increase the problem for controlling program in 
these countries (Dolin et al., 1993, and Glynn et al., 
2002). 
 
The notification rate of TB for the developing 
countries estimated to increase in greater amount 
with variation between countries between 1980- 
2000 years that more indicated in below the table 2. 
 
Table 1: Notification rates of TB for some of   developed countries between 1980 -2002 years. 
 
Countries Years 
Change in rates 
per 1,00,000 
Sources 
England and Wales 1988-2002 9.3-13.2% Akhtar  and Antoine, 2001 
Australia 1986-1995 5.2-7.6% Heath et al., 1998 
France 1980-2000 17.2-6.12% WHO, 2007 
USA 1980-2000 27.7-16.3% WHO, 2007 
Italy 1980-1998 3.3-5.7% WHO, 2007 
Mexico 1980-2003 1.25-18.43% WHO, 2007 
Canada 1980-2000 2.76-1.67% WHO, 2007 
 




rates in percent 
Sources 
Ethiopia 1980-2000 40.1-91.1% WHO, 2007 
South Africa 1980-2000 55.3-151.24% WHO, 2007 
Kenya 1980-2000 11.05-64.16% WHO, 2007 
Central Republic of Africa 1980-1999 0.66-5% WHO, 2007 
Egypt 1980-2000 0.004-0.016% WHO, 2007 
Brazil 1980-2000 72.6-77.9% WHO, 2007 
Bangladesh 1980-2003 9.7-75.6% WHO, 2007 
 
Current Epidemiology of Tuberculosis  
According to the World Health Organization 
(WHO), currently nearly 2 billion people 
approximately one–third of the world's population 
have been exposed to TB pathogen. Annually, 8 
million people become ill with TB, and 2 million 
people die from the disease worldwide (CDC, 2005). 
In 2004, around 14.6 million people had active TB 
disease with 9 million new cases  while in 2005, 
total of 4.8 million new cases of TB were notified 
from all sources. This represents 55% of the 8.8 
million estimated new cases; the 2.4 million new 
smear-positive cases notified account for 62% of the 
3.9 million estimated (WHO, 2006). 
 
The detection rate of new smear-positive cases 
from all sources increased slowly and linearly from 
1995 to 2001 and then more quickly from 2002 to 
2005 (WHO, 2007). While in 2006, 9.2 million (139 
per 100 000) new cases of TB estimate occurred 
that including 4.1 million (62 per100 000) new 
smear-positive cases. Among the 9.2 million new 
cases of TB in 2006, WHO estimated that around 
709, 000 (7.7%) were HIV-positive.  In terms of 
incident cases, India, China, Indonesia, South Africa 




and Nigeria rank first to fifth (WHO, 2008). Asia 
(South-East Asia and Western Pacific regions) 
accounts for 55% of global cases, and Africa 
accounts for 31%; the other three regions account 
for relatively small fractions of global cases. 
 
In 2000, it has been estimated that approximately 
40% of   HIV-attributable TB cases has been 
occurred in sub-Saharan Africa and 40% in 
Southeast Asia (Dolin et al., 1993).The rest of the 
African Region accounted for a further 61% of HIV-
infected TB cases in 2005, and 19% of all cases of 
TB in adult HIV-positive people was live in South 
Africa . Like to previous years, currently in 2006, the 
African Region accounts for most HIV-associated 
TB case (85%). The remaining most of cases (6%) 
are in the South-East Asia Region, mainly in India. 
 
The current trend of TB was more indicted from 
the data of TB patient that registered in national 
surveillance systems and reported to WHO between 
1980 and 2005, where 90 million TB patients 
registered, from these more than 26 million were 
notified by DOTS programmes since 1995. This vast 
body of surveillance data suggests that the global 
TB incidence rate peaked some time between 2000 
and 2005, although the total number of new cases is 
still rising each year. The global TB epidemic is now 
on the threshold of decline (WHO, 2008). This was 
more indicated from the data from 93 countries from 
1997 to 2006 years which indicated that global 
incidence rate of TB peaked around 2002 and 
appears now to have stabilized or begun to decline. 
In 66 of these 93 countries, the rate of decline was 
between zero and 6% per year WHO, 2007, and 
WHO, 2008). Similarly, incidence rate is now stable 
or falling in all six WHO regions. However, the slow 
decline in incidence rates per capita is offset by 
population growth. Consequently, the number of 
new cases arising each year is still increasing 
globally and in the WHO regions of Africa, the 
Eastern Mediterranean and South-East Asia (WHO, 
1994). 
 
Therefore, the current decline in TB 
epidemiology may be promising result in the control 
of TB in the future, and the supposed contributing 
factor for this change in the trend of TB are 
increasing in Global DOTS and children BCG 
Vaccination coverage, increasing in health services 
centers, increasing in human awareness, and the 
strength of the national and Global controlling 
program of TB. 
 
Future Epidemiology of Tuberculosis  
Even though, the global TB incidence shows 
some decline from 2000-2006, it will be  expected to 
be worsen in the immediate future, as a result of 
demographic factors (population growth), MDR and 
changes in age structure of the population and 
increase in HIV sero-prevalence rates, especially in 
developing countries of  South-east Asia and Sub-
Saharan Africa (WHO, 2007).  
 
Dye models show that TB is on the increasing 
and that the number of cases grew 1.7% per year 
from 1997 to 2000 and the trends indicted that more 
9-10 million new cases will be occurred in 2010 
(McKenna et al., 1995). This shows that the 
incidence of TB will increase by 17% in 2010 in 
comparing to 2000. Three fourths of this increase is 
expected to be due to demographic factors and the 
rest from a balance between decline in incidence 
due to intervention measures and increase in 
incidence due to HIV epidemic. Much higher relative 
increase is predicted in developing countries 
compared to Western Europe and other developed 
countries. Africa and south East Asian regions are 
predicted to account for three –fourths of this 
increase in global incidence of TB (Chadha, 1997). 
 
In addition, as the drug resistance spreads, TB 
threatens to become an incurable disease for future 
generations and TB deaths will rise further, also 
because of higher mortality of HIV associated TB 
(Dolin et al., 1993).  WHO (2005) estimates that, if 
unchecked, the current TB epidemic would infect 1 
billion people between 2000 and 2020, of whom 200 
million will develop fully active TB and 35 million will 
die (Joana et al., 2004).   
 
Epidemiology of Tuberculosis in Ethiopia 
According to the WHO (2008) estimate, Ethiopia 
ranks top 7
th
 in the world, and top 3
rd 
 in Africa in the 
lists of high burden countries for TB, with estimated  
incidence of 379 per 100,000 populations for all 
forms TB and 162 per 100,000 populations for 
smear positive TB. According to this estimate, the 
national trend of TB incidence shows -1.3 % 
decreases in the years from 2005-2006. The 
prevalence and mortality of all forms of TB was 
estimated to be 643 and 84 per 100,000 
populations, respectively [33]. Besides, according to 
National TB report, in the years 2006/7 in Ethiopia a 
total of 126,106 TB cases was notified to the 
National Tuberculosis and Leprosy Control Program 
(NTLCP), which was lower than the 2005/6 
notification where 126,233 TB cases were notified. 
From the 2006/7 notified TB cases, 36% (45,112), 
30% (377,915) and 34% were ETB, new smear 
positive PTB and new smear negative PTB, 
respectively (WHO, 2005). 
According to the FMOH (Federal Minster of 
Health) hospital statistical data, TB is the leading 
causes of morbidity, the third causes of hospital 
admission (after deliveries and malaria), and the 
second causes of death in Ethiopia (after malaria). 
TB is an obstacle to soci-economic development in 




Ethiopia, sine this disease affect 75% of cases with 
in economically productive age group of 15-54 years 
(FMOH, 2007).  
 
Another challenge of TB control in Ethiopia is the 
emergence of multi-drug resistant TB (MDR-TB). 
According to the data from the survey conducted in 
the country between 2003-2006, the levels of MDR-
TB were 1.6% and 11.8% in new and re-treatment 
cases of TB patients, respectively (FMOH, 2007). 
 
The national standard TB prevention and control 
program is incorporated in to the DOTS program 
was started as pilot in Arise and Bale Zone, Oromia 
Regional State in 1992. This strategy has been 
subsequently scaled up in the country and currently 
reached at the level of 90% of geographical and 
75% of health facility coverage. Besides, to strength 
the national TB control strategies combination of TB 
and leprosy control strategies was decided in 1994 
as National TB and Leprosy Control Program 
(NTLCP) (FMOH, 2007). 
 
CONCLUSION  
TB has been present in humans since ancient 
history and it is becoming one of a leading life threat 
disease both in developed and developing countries 
especially in the era of HIV/ADIS. It causes most 
widespread public concern and problem in the 
human history including in the first decay of 21 
centuries as an endemic disease in many part of 
both developed and developing countries. 
 
In the early 20century, before introduction of 
chemotherapy, the trend of TB shows to decline in 
developed countries due to change in life standard 
while it is still great problem in developing countries, 
and many activities that had been done to control 
TB are stopped in developed countries that lead to 
TB resurgence in developed counties in line with 
change in Scio–demographic, emergence of MDR-
TB, and HIV epidemic, and these factors 
aggravated further the problem in developing 
countries. Thus, TB is one of a leading health 
problem both in developing and developed countries 
throughout human history.  
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